SEC Comment Letter 0000000000-23-002679 to Oak Street Health, Inc. (CIK 0001564406)
Oak Street Health, Inc. (CIK 0001564406)
Date: March 17, 2023 · CIK: 0001564406 · Accession: 0000000000-23-002679
AI Filing Summary & Sentiment
File numbers found in text: 001-39427
Letter
United States securities and exchange commission logo March 17, 2023 Mike Pykosz Chief Executive Officer Oak Street Health, Inc. 30 W. Monroe Street, Suite 1200 Chicago, Illinois 60603 Re:Oak Street Health, Inc. Preliminary Proxy on Schedule 14A Filed March 9, 2023 File No. 001-39427 Dear Mike Pykosz: We have reviewed your filing and have the following comment. In our comment we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Proxy on Schedule 14A, Filed March 9, 2023 General 1.It appears that Mike Pykosz, the company’s Chief Executive Officer, Chairman and Director, will remain the Chief Executive Officer of the company upon the closing of the transaction. Please tell us the role of the CEO and possibly other senior management who were involved in the negotiations and why you believe no such person is an affiliate engaged, directly or indirectly, in the going private transaction. For guidance, refer to Questions 201.01 and 201.05 of the Division of Corporation Finance’s Compliance and Disclosure Interpretations of Going Private Transactions, Exchange Act Rule 13e-3, and Schedule 13E-3.
FirstName LastNameMike Pykosz Comapany NameOak Street Health, Inc. March 17, 2023 Page 2 FirstName LastName Mike Pykosz Oak Street Health, Inc. March 17, 2023 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Jordan Nimitz at 202-551-5831 or Celeste Murphy at 202-551-3257 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Daniel Wolf, Esq.
Show Raw Text
United States securities and exchange commission logo
March 17, 2023
Mike Pykosz
Chief Executive Officer
Oak Street Health, Inc.
30 W. Monroe Street, Suite 1200
Chicago, Illinois 60603
Re:Oak Street Health, Inc.
Preliminary Proxy on Schedule 14A
Filed March 9, 2023
File No. 001-39427
Dear Mike Pykosz:
We have reviewed your filing and have the following comment. In our comment we may
ask you to provide us with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Proxy on Schedule 14A, Filed March 9, 2023
General
1.It appears that Mike Pykosz, the company’s Chief Executive Officer, Chairman and
Director, will remain the Chief Executive Officer of the company upon the closing of the
transaction. Please tell us the role of the CEO and possibly other senior management who
were involved in the negotiations and why you believe no such person is an affiliate
engaged, directly or indirectly, in the going private transaction. For guidance, refer to
Questions 201.01 and 201.05 of the Division of Corporation Finance’s Compliance and
Disclosure Interpretations of Going Private Transactions, Exchange Act Rule 13e-3, and
Schedule 13E-3.
FirstName LastNameMike Pykosz
Comapany NameOak Street Health, Inc.
March 17, 2023 Page 2
FirstName LastName
Mike Pykosz
Oak Street Health, Inc.
March 17, 2023
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Jordan Nimitz at 202-551-5831 or Celeste Murphy at 202-551-3257
with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Daniel Wolf, Esq.